Teva Pharmaceutical Industries (TEVJF) Goodwill (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Goodwill across 18 years of filings, most recently posting $15.8 billion for Q1 2026.

• Quarterly Goodwill rose 2.23% year-over-year to $15.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.8 billion (up 2.23% YoY) and the FY2025 annual result came in at $16.0 billion, changed 0.0% from the prior year.
• Goodwill declined to $15.8 billion in Q1 2026, from $16.0 billion in the prior quarter.
• Over five years, Goodwill peaked at $20.0 billion in Q1 2022 and troughed at $479.0 million in Q2 2022.
• A 5-year average of $15.9 billion and a median of $16.5 billion in 2024 frame the typical range for Goodwill.
• Annual changes were most pronounced in 2022 — Goodwill sank 97.65% — and 2023, when it surged 3473.7%.
• Tracing TEVJF's Goodwill over 5 years: stood at $17.2 billion in 2022, then changed by 0.0% to $17.2 billion in 2023, then decreased by 6.85% to $16.0 billion in 2024, then changed by 0.0% to $16.0 billion in 2025, then declined by 1.11% to $15.8 billion in 2026.
• Business Quant data shows TEVJF's Goodwill at $15.8 billion in Q1 2026, $16.0 billion in Q4 2025, and $15.9 billion in Q3 2025.